Hypertension
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Be aged between 18 and 80; 2.Patients with diagnosed hypertension who are taking medication or newly diagnosed with hypertension; 3.Screening high-risk patients with primary aldosteronism using chemiluminescence method: renin concentration 5ng/dL or aldosterone/renin>=3.7; 4.Agree to be enrolled for examination and evaluation;
Exclusion criteria
Exclusion criteria: 1.Acute and chronic renal insufficiency: eGFR 25ng/dl (considered as the possibility of unilateral disease is high, excluded); 3.oral spironolactone, sodium channel blockers such as class I antiarrhythmic drugs, potassium sparing diuretics such as amphetamine, liquorice extract, potassium excreting diuretics, and oral contraceptives containing hormone therapy such as estrogen; 4.acute stage of serious cardiovascular and cerebrovascular diseases: acute coronary syndrome, acute heart failure, new cerebral hemorrhage, new cerebral infarction, etc; 5.malignant tumor; 6.pregnancy or preparation for pregnancy during the study; 7.do not sign the informed consent form and do not want to be followed up for 3 months; 8.other conditions that cannot cooperate with the examination and treatment (such as disability, dementia, mental illness, etc.);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24-hour urinary aldosterone measured by Chemiluminescence;24-hour urinary aldosterone measured by liquid chromatography / tandem mass spectrometry;Sitting aldosterone levels before and after saline loading test;Aldosterone levels before and after captopril test;Accuracy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sensitivity;Specificity; | — |
Countries
China
Contacts
Beijing Haidian Hospital